Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.
Official title: A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-05-23
Completion Date
2027-05
Last Updated
2026-01-05
Healthy Volunteers
No
Conditions
Interventions
ZG005 for Injection
intravenous infusion
Gecacitinib Hydrochloride Tablets
Oral
Locations (1)
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China